Earnings summaries and quarterly performance for Tectonic Therapeutic.
Executive leadership at Tectonic Therapeutic.
Board of directors at Tectonic Therapeutic.
Research analysts covering Tectonic Therapeutic.
Recent press releases and 8-K filings for TECX.
Tectonic Therapeutics Updates on Clinical Pipeline at TD Cowen Conference
TECX
New Projects/Investments
Guidance Update
- Tectonic Therapeutics is advancing two clinical programs: TX-45, a long-acting relaxin in Phase 2 for pulmonary hypertension associated with preserved ejection fraction heart failure (PH-HFpEF) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), and TX-2100, a potential first-in-class APJ antagonist in Phase 1 for hereditary hemorrhagic telangiectasia (HHT).
- Key upcoming catalysts include results from the Phase 2 APEX study for TX-45 in PH-HFpEF expected in late 2026 or early 2027, and Phase 1 data for TX-2100 by Q4 2026.
- Early clinical data for TX-45 in PH-HFpEF patients demonstrated significant improvements, including an almost 19% reduction in pulmonary capillary wedge pressure and over 30% reduction in pulmonary vascular resistance in patients with abnormally high PVR.
- The company is well-capitalized to advance its pipeline, which targets high unmet need areas with multi-billion dollar market potential, such as PH-HFpEF (estimated 1 million patients in the U.S.) and HHT (second most common genetic bleeding disorder with no approved therapies).
2 days ago
Tectonic Therapeutics Provides Pipeline Update at TD Cowen 46th Annual Healthcare Conference
TECX
New Projects/Investments
Product Launch
- Tectonic Therapeutics is advancing two clinical programs: TX-45, a long-acting relaxin in Phase 2 for pulmonary hypertension associated with preserved ejection fraction heart failure (PH-HFpEF) and newly initiated Phase 2 for pulmonary hypertension associated with interstitial lung disease (PH-ILD); and TX-2100, a potential first-in-class APJ antagonist that just entered Phase 1 for hereditary hemorrhagic telangiectasia (HHT).
- Key data readouts are anticipated for TX-45's Phase 2 PH-HFpEF study in late 2026 or early 2027, and for TX-2100's Phase 1 study by Q4 2026, with plans to initiate Phase 1B and Phase 2 studies for TX-2100 shortly thereafter.
- Both programs target areas of high unmet medical need with significant market potential, including an estimated 1 million patients in the U.S. for PH-HFpEF and a multi-billion dollar market for HHT, where there are currently no approved therapies.
- The company has demonstrated supporting clinical evidence for TX-45 from a Phase 1B study in PH-HFpEF patients, showing improvement in left heart function and pulmonary hemodynamics, and is well-capitalized to advance its pipeline.
2 days ago
Tectonic Therapeutic Announces Q4 and Full Year 2025 Financial Results and Business Highlights
TECX
Earnings
Guidance Update
New Projects/Investments
- Tectonic Therapeutic reported a net loss of $19.2 million for the fourth quarter of 2025 and $74.2 million for the full year 2025.
- As of December 31, 2025, cash and cash equivalents were $253.8 million, providing an expected cash runway into Q4 2028.
- The company announced positive topline results from the TX45 Phase 1b clinical trial in October 2025, advanced TX2100 into Phase 1a, and initiated a second TX45 Phase 2 clinical trial in February 2026. TX45 APEX Phase 2 topline results are expected in 2026, and TX2100 Phase 1a topline results in Q4 2026.
- Fran\u00e7ois Nader, M.D., MBA, was appointed as an independent director and will assume the role of Chair of the Board, effective April 1, 2026.
8 days ago
Tectonic Therapeutic Discusses TX2100 for HHT and Provides Clinical Trial Update
TECX
New Projects/Investments
- Tectonic Therapeutic held a KOL event to discuss TX2100, a potential first-in-class APJ antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), an orphan disease with a potential multi-billion dollar market and no approved therapies.
- The first-in-human Phase I trial for TX2100 has been initiated in Australia, with top-line results expected by Q4 2026.
- TX2100 is a subcutaneously administered treatment designed as a differentiated, pathology-biased anti-angiogenic therapy with the potential for improved safety compared to current off-label treatments.
- Preclinical data demonstrated robust efficacy in two HHT mouse models and a clean safety profile in toxicology studies, supporting its advancement into clinical trials.
- Tectonic plans to initiate an open-label Phase Ib trial in severe HHT patients and a Phase II placebo-controlled proof-of-concept study in moderate to severe HHT patients, with potential for expansion into other bleeding disorders.
Feb 24, 2026, 4:00 PM
Tectonic Therapeutic provides update on TX2100 clinical development for HHT
TECX
Product Launch
New Projects/Investments
Guidance Update
- Tectonic Therapeutic highlighted TX2100, a potential first-in-class APJ antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), an orphan disease with no approved therapies and a potential multi-billion dollar market.
- TX2100 is designed to offer a differentiated approach to HHT treatment, providing anti-angiogenic benefits with improved safety and durability compared to current off-label therapies, based on its pathology-biased mechanism.
- Preclinical data demonstrated robust efficacy in HHT models, including reductions in arteriovenous malformations (AVMs) and bleeding, and increases in hemoglobin, alongside a clean safety profile in non-human primate toxicology studies.
- The first-in-human Phase I trial for TX2100 has commenced in Australia, with the first two subjects successfully dosed, and top-line results are anticipated by 4Q 2026.
- Tectonic plans to initiate parallel Phase Ib and Phase II trials in HHT patients, exploring efficacy endpoints such as epistaxis and requirements for iron/blood transfusions.
Feb 24, 2026, 4:00 PM
Tectonic Therapeutic Initiates Phase I Trial for HHT Treatment TX2100
TECX
New Projects/Investments
Guidance Update
- Tectonic Therapeutic hosted a KOL event to discuss TX2100, a potential first-in-class APJ antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), a serious genetic bleeding disorder with no approved therapies.
- TX2100 is a subcu-administered APJ antagonist designed to provide pathology-biased anti-angiogenic efficacy with improved safety and durability compared to existing off-label anti-angiogenic therapies.
- Preclinical data demonstrated robust efficacy in two HHT models, showing reductions in AVMs and bleeding, and increases in hemoglobin, supported by a clean safety profile in GLP toxicology studies.
- The Phase I first-in-human trial for TX2100 has been initiated in healthy volunteers in Australia, with top-line results anticipated by Q4 2026.
- Tectonic plans to advance TX2100 into an open-label Phase Ib trial in severe HHT patients and a Phase II placebo-controlled proof-of-concept study in moderate to severe HHT patients, with potential for expansion into other bleeding disorders.
Feb 24, 2026, 4:00 PM
Tectonic Provides APEX Study Update and Financial Runway
TECX
Guidance Update
New Projects/Investments
- Tectonic's APEX study enrollment is on track for its end-of-year recruitment goal, and the company expects to narrow guidance on enrollment completion by the end of Q1 2026.
- The Data Safety Monitoring Committee (DSMB) for the APEX study reported no safety signal as of its last meeting at the end of September.
- Tectonic's TX45 is differentiated from competitors by its longer half-life, which is expected to enable monthly dosing compared to Lilly's weekly and AstraZeneca's every other week dosing.
- The company plans to submit regulatory documents for its TX2100 healthy volunteer study around December 2, 2025, with the study anticipated to start in early 2026.
- Tectonic has a cash runway into Q4 2028, with approximately $268 million in cash at its last quarterly earnings.
Dec 2, 2025, 8:30 PM
Tectonic Provides Update on APEX Study Enrollment, TX2100 Development, and Cash Runway
TECX
Guidance Update
New Projects/Investments
- Tectonic expects to narrow guidance on APEX study enrollment completion by the end of Q1 2026, having met internal recruitment objectives for mid-year and being on track for end-of-year goals. The study's Data Safety Monitoring Board (DSMB) reported no safety signal in late September and recommended the continuous plan.
- The APEX study is now exclusively recruiting patients with a PVR greater than three, a subset representing 70% of the total population, based on the hypothesis of greater benefit in this group.
- Tectonic's TX45 is differentiated from competitors by its longer half-life, which is expected to enable monthly dosing, in contrast to weekly for Lilly's and every other week for AstraZeneca's relaxin fusions.
- The company plans to submit regulatory documents for TX2100 today or tomorrow and anticipates starting a healthy volunteer study in early 2026 (1Q).
- Tectonic reports a cash runway extending into Q4 2028, with approximately $268 million in cash at its last quarterly earnings.
Dec 2, 2025, 8:30 PM
Tectonic Provides Update on APEX Study Progress and Financials
TECX
Guidance Update
New Projects/Investments
Financials
- Tectonic (TECX) is on track to meet its end-of-year recruitment goal for the APEX study and expects to narrow guidance on enrollment completion by the end of Q1 2026.
- The Data Safety Monitoring Committee (DSMB) for the APEX study reported no safety signal at its last meeting in late September, recommending continuation of the plan.
- The APEX study has completed enrollment for patients with PVR less than three and is now only recruiting patients with a PVR greater than three, which represents 70% of the total population.
- Tectonic's TX45 has a longer half-life compared to competitors, potentially enabling monthly dosing. The company also reported a cash runway into Q4 2028 with approximately $268 million in cash at its last quarterly earnings.
Dec 2, 2025, 8:30 PM
Tectonic Therapeutic Announces Q3 2025 Financial Results and Business Highlights
TECX
Earnings
New Projects/Investments
Guidance Update
- Tectonic Therapeutic, Inc. reported cash and cash equivalents of $268.4 million as of September 30, 2025, with an anticipated cash runway into Q4 2028.
- For the three months ended September 30, 2025, the company recorded a net loss of $19.0 million, compared to a net loss of $17.7 million for the same period in 2024.
- Research and development expenses were $16.9 million for Q3 2025, an increase from $14.3 million in Q3 2024, primarily due to the discovery, development, and manufacturing of TX2100 and increased employee-related expenses.
- The company announced positive topline data from Part B of the TX45 Phase 1b trial and expects to initiate the TX2100 Phase 1 clinical trial in Q1 2026.
- The TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026, and topline results for the ongoing TX45 APEX Phase 2 clinical trial are also expected in 2026.
Nov 6, 2025, 9:15 PM
Fintool News
In-depth analysis and coverage of Tectonic Therapeutic.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more